Ethanol-Cannabinoid Interaction in the Regulation of Neurogenesis

乙醇-大麻素相互作用在神经发生调节中的作用

基本信息

项目摘要

Chronic ethanol treatment has been shown to inhibit adult brain hippocampal and forebrain neurogenesis and to decrease brain CB1 cannabinoid receptor (CB1R) expression. There are two different types of cannabinoid receptors in brain, CB1R and CB2 cannabinoid receptor (CB2R). In brain CB1R are primarily neuronal, whereas CB2 cannabinoid receptor (CB2R) are primarily present on glia, particularly microglia and both receptors have been implicated in the regulation neuroprogenitor stem cell (NPC) proliferation, differentiation and neurogenesis. Chronic ethanol also increases brain microglial markers and proinflammatory cytokine expression. Interestingly, endotoxin (LPS), causes brain microglial activation, increased CB2R, increased proinflammatory cytokine expression and loss of neurogenesis. These studies and others support the overall hypothesis that CB1R and CB2R contribute to ethanol-mediated inhibition of neurogenesis. To test this hypothesis we have developed the following 3 specific aims: Aim 1. To define the role of CB1 receptors In ethanol inhibition of neurogenesis. This aim will characterize the role(s) of CB1R in ethanol inhibition of neurogenesis using ethanol time course and dose response comparisons of changes in neurogenesis and CB1R as well as administration of CB1R agonists and antagonists as well as CB1R knockout (KO) transgenic mice (CB1[-/-]). Confocal microscopy will allow determination of NPC neurogenesis and receptor expression on NPC. Aim 2. To determine the role of CB2R in ethanol and endotoxin (LPS) inhibition of neurogenesis. This aim will test the hypothesis that ethanol induced microglial activation, expression of CB2 receptors and proinflammatory cytokines reduce neurogenesis. Preliminary studies and others indicate that LPS induction of proinflammatory cytokines increases CB2R and inhibits neurogenesis. Ethanol potentiates LPS induction of proinflammatory cytokines, but the effect on CB2R and neurogenesis are not known. Time course and dose response comparisons of changes in neurogenesis, microglia, and CB2R expression will be determined in neurogeneic regions. Ethanol alone, LPS alone and combined ethanol-LPS provide progressively increased proinflammatory responses for comparisons with neurogenesis. CB2R agonists and antagonists as well as CB2R-K0 transgenic mice (CB2[-/-]) will be employed to characterize the role(s) of the CB2R receptors in ethanol ¿ LPS inhibition of neurogenesis. Aim. 3. To define the role of endogenous cannabinoids on ethanol inhibition of neurogenesis. This aim will determine the role of endogenous cannabinoids activation in ethanol regulation of neurogenesis by blocking degradation of endogenous cannabinoid as well as anti-inflammatory drugs and anti-oxidants known to block endotoxin and/or ethanol effects. Studies suggest ethanol increases endogenous CB that act on and down regulate CBR1, yet CBR1 activation increases neurogenesis. How ethanol, endogenous CB and CBR1 impact ethanol inhibition of neurogenesis will be determined. It is expected that NPC downregulation of CBR1 will be independent of endogenous CB stimulation and related to changes in proinflammatory gene induction and loss of neurogenesis. Together these studies will provide a detailed insight into the signaling pathway that regulates the effects of ethanol and cannabinoids on neurogenesis as well as discovering potential in vivo neurogenic therapies.
研究表明,长期乙醇治疗可抑制成人大脑海马和前脑神经发生,并减少大脑CB 1大麻素受体(CB 1 R)的表达。脑中存在两种不同类型的大麻素受体,CB 1 R和CB 2大麻素受体(CB 2 R)。在脑中,CB 1受体主要是神经元受体,而CB 2受体主要存在于神经胶质细胞,特别是小胶质细胞上,并且这两种受体都涉及调节神经祖干细胞(NPC)。 增殖、分化和神经发生。慢性乙醇也会增加脑小胶质细胞标记物和促炎细胞因子的表达。有趣的是,内毒素(LPS)导致脑小胶质细胞活化、CB 2 R增加、促炎细胞因子表达增加和神经发生丧失。这些研究和其他研究支持CB 1 R和CB 2 R有助于乙醇介导的神经发生抑制的总体假设。为了验证这一假设,我们制定了以下3个具体目标: 目标1.目的明确CB 1受体在乙醇抑制神经发生中的作用。该目的将使用神经发生和CB 1 R变化的乙醇时程和剂量反应比较以及CB 1 R激动剂和拮抗剂以及CB 1 R敲除(KO)转基因小鼠(CB 1 [-/-])给药来表征CB 1 R在乙醇抑制神经发生中的作用。共聚焦显微镜将允许确定NPC神经发生和NPC上的受体表达。 目标2.目的探讨CB 2 R在乙醇和内毒素(LPS)抑制神经发生中的作用。这一目标将测试的假设,乙醇诱导的小胶质细胞活化,表达CB 2受体和促炎细胞因子减少神经发生。初步研究和其他研究表明,LPS诱导的促炎细胞因子增加CB 2 R并抑制神经发生。乙醇增强LPS诱导促炎细胞因子,但对CB 2 R和神经发生的影响尚不清楚。将比较神经发生、小胶质细胞和CB 2 R表达变化的时间过程和剂量反应。 在神经发生区域决定。单独的乙醇、单独的LPS和组合的乙醇-LPS提供与神经发生相比逐渐增加的促炎反应。将采用CB 2 R激动剂和拮抗剂以及CB 2 R-K 0转基因小鼠(CB 2 [-/-])来表征CB 2 R受体在乙醇?LPS抑制神经发生中的作用。 瞄准3.确定内源性大麻素在乙醇抑制神经发生中的作用。这一目标将确定内源性大麻素激活在乙醇调节神经发生中的作用,通过阻断内源性大麻素的降解以及已知阻断内毒素和/或乙醇作用的抗炎药和抗氧化剂。研究表明,乙醇增加了作用于CBR 1并下调CBR 1的内源性CB,但CBR 1激活增加了神经发生。将确定乙醇、内源性CB和CBR 1如何影响乙醇对神经发生的抑制。预计NPC下调CBR 1将独立于内源性CB刺激,并与促炎基因诱导的变化和神经发生的丧失有关。 这些研究将为调节乙醇和大麻素对神经发生的影响的信号通路提供详细的见解,并发现潜在的体内神经源性疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Somnath Mukhopadhyay其他文献

Somnath Mukhopadhyay的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Somnath Mukhopadhyay', 18)}}的其他基金

Ethanol-Cannabinoid Interaction in the Regulation of Neurogenesis
乙醇-大麻素相互作用在神经发生调节中的作用
  • 批准号:
    8123739
  • 财政年份:
    2010
  • 资助金额:
    $ 2.29万
  • 项目类别:
CB2 Cannabinoid Receptor-mediated Regulation of Prostate Cancer Growth
CB2 大麻素受体介导的前列腺癌生长调节
  • 批准号:
    8068484
  • 财政年份:
    2010
  • 资助金额:
    $ 2.29万
  • 项目类别:
Ethanol-Cannabinoid Interaction in the Regulation of Neurogenesis
乙醇-大麻素相互作用在神经发生调节中的作用
  • 批准号:
    8381571
  • 财政年份:
  • 资助金额:
    $ 2.29万
  • 项目类别:
RC3 Ethanol-Cannabinoid Interaction in the Regulation of Neurogenesis
RC3 乙醇-大麻素相互作用在神经发生调节中的作用
  • 批准号:
    8013696
  • 财政年份:
  • 资助金额:
    $ 2.29万
  • 项目类别:
Ethanol-Cannabinoid Interaction in the Regulation of Neurogenesis
乙醇-大麻素相互作用在神经发生调节中的作用
  • 批准号:
    8307389
  • 财政年份:
  • 资助金额:
    $ 2.29万
  • 项目类别:
Ethanol-Cannabinoid Interaction in the Regulation of Neurogenesis
乙醇-大麻素相互作用在神经发生调节中的作用
  • 批准号:
    8508763
  • 财政年份:
  • 资助金额:
    $ 2.29万
  • 项目类别:
CB2 Cannabinoid Receptor-mediated Regulation of Prostate Cancer Growth
CB2 大麻素受体介导的前列腺癌生长调节
  • 批准号:
    8332122
  • 财政年份:
  • 资助金额:
    $ 2.29万
  • 项目类别:
CB2 Cannabinoid Receptor-mediated Regulation of Prostate Cancer Growth
CB2 大麻素受体介导的前列腺癌生长调节
  • 批准号:
    8381982
  • 财政年份:
  • 资助金额:
    $ 2.29万
  • 项目类别:
RC3 Ethanol-Cannabinoid Interaction in the Regulation of Neurogenesis
RC3 乙醇-大麻素相互作用在神经发生调节中的作用
  • 批准号:
    8508761
  • 财政年份:
  • 资助金额:
    $ 2.29万
  • 项目类别:
RC3 Ethanol-Cannabinoid Interaction in the Regulation of Neurogenesis
RC3 乙醇-大麻素相互作用在神经发生调节中的作用
  • 批准号:
    8307385
  • 财政年份:
  • 资助金额:
    $ 2.29万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 2.29万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 2.29万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 2.29万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 2.29万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 2.29万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 2.29万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 2.29万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 2.29万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 2.29万
  • 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
  • 批准号:
    10534864
  • 财政年份:
    2023
  • 资助金额:
    $ 2.29万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了